TY - JOUR AU - Rashidi, A. AU - Walter, R. B. PY - 2016 DA - 2016// TI - Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here? JO - Expert Rev Hematol. VL - 9 UR - https://doi.org/10.1586/17474086.2016.1142868 DO - 10.1586/17474086.2016.1142868 ID - Rashidi2016 ER - TY - JOUR AU - Walter, R. B. PY - 2018 DA - 2018// TI - Investigational CD33-targeted therapeutics for acute myeloid leukemia JO - Expert Opin Investig Drugs. VL - 27 UR - https://doi.org/10.1080/13543784.2018.1452911 DO - 10.1080/13543784.2018.1452911 ID - Walter2018 ER - TY - JOUR AU - Hills, R. K. AU - Castaigne, S. AU - Appelbaum, F. R. AU - Delaunay, J. AU - Petersdorf, S. AU - Othus, M. PY - 2014 DA - 2014// TI - Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials JO - Lancet Oncol. VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70281-5 DO - 10.1016/S1470-2045(14)70281-5 ID - Hills2014 ER - TY - JOUR AU - Loke, J. AU - Khan, J. N. AU - Wilson, J. S. AU - Craddock, C. AU - Wheatley, K. PY - 2015 DA - 2015// TI - Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia JO - Ann Hematol. VL - 94 UR - https://doi.org/10.1007/s00277-014-2218-6 DO - 10.1007/s00277-014-2218-6 ID - Loke2015 ER - TY - JOUR AU - Walter, R. B. AU - Gooley, T. A. AU - Velden, V. H. AU - Loken, M. R. AU - Dongen, J. J. AU - Flowers, D. A. PY - 2007 DA - 2007// TI - CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy JO - Blood VL - 109 UR - https://doi.org/10.1182/blood-2006-09-047399 DO - 10.1182/blood-2006-09-047399 ID - Walter2007 ER - TY - JOUR AU - Pollard, J. A. AU - Loken, M. AU - Gerbing, R. B. AU - Raimondi, S. C. AU - Hirsch, B. A. AU - Aplenc, R. PY - 2016 DA - 2016// TI - CD33 expression and its association with gemtuzumab ozogamicin response: results from the randomized phase III Children’s Oncology Group trial AAML0531 JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.62.6846 DO - 10.1200/JCO.2015.62.6846 ID - Pollard2016 ER - TY - JOUR AU - Olombel, G. AU - Guerin, E. AU - Guy, J. AU - Perrot, J. Y. AU - Dumezy, F. AU - Labarthe, A. PY - 2016 DA - 2016// TI - The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia JO - Blood VL - 127 UR - https://doi.org/10.1182/blood-2016-01-689976 DO - 10.1182/blood-2016-01-689976 ID - Olombel2016 ER - TY - JOUR AU - Khan, N. AU - Hills, R. K. AU - Virgo, P. AU - Couzens, S. AU - Clark, N. AU - Gilkes, A. PY - 2017 DA - 2017// TI - Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia JO - Leukemia VL - 31 UR - https://doi.org/10.1038/leu.2016.309 DO - 10.1038/leu.2016.309 ID - Khan2017 ER - TY - JOUR AU - Lamba, J. K. AU - Chauhan, L. AU - Shin, M. AU - Loken, M. R. AU - Pollard, J. A. AU - Wang, Y. C. PY - 2017 DA - 2017// TI - CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: report from randomized phase III Children’s Oncology Group trial AAML0531 JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.71.2513 DO - 10.1200/JCO.2016.71.2513 ID - Lamba2017 ER - TY - JOUR AU - Gale, R. E. AU - Popa, T. AU - Wright, M. AU - Khan, N. AU - Freeman, S. D. AU - Burnett, A. K. PY - 2018 DA - 2018// TI - No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials JO - Blood VL - 131 UR - https://doi.org/10.1182/blood-2017-08-802157 DO - 10.1182/blood-2017-08-802157 ID - Gale2018 ER -